PV Reporter

20/03/2026

Abstract: Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis

Ruxolitinib and subsequent JAK2 inhibitors have improved care for some patients with the myeloproliferative neoplasms myelofibrosis, essential thrombocythe

17/03/2026

📰 Metformin Reduces BM Fibrosis and JAK-STAT Signaling in PMF

Metformin associated w/ reductions in bone marrow fibrosis, downregulation of key oncogenic signaling pathways in pts w/ primary myelofibrosis.

11/03/2026

I’m excited to share a new resource with the MPN community! The MPN Clinical Trial Finder is now live in BETA and available for everyone to use. 🚀

David Wallace, your PV Reporter, created this tool to serve our community and make the process of finding relevant clinical trials easier. It is completely free, and I’ve designed it so that no personal information is required to use it.

Check it out here: https://pvreporter.com/mpn-clinical-trial-finder/

A quick tip: If you receive a "nothing found" message, try clearing some of the search fields or refreshing your screen to reset the parameters. Please take a look and let me know your feedback, as I work to refine things as needed.

04/03/2026

🦷 Are your medications affecting your dental health?

If you're living with a myeloproliferative neoplasm (MPN) like Polycythemia Vera or MF and taking pegylated interferon or ruxolitinib, your mouth may be paying a price, and your doctor might not even know to ask.

A 2020 study found that nearly 1 in 5 MPN patients had needed unexpected dental care, including spontaneous tooth cracks, tooth loss, and gum abscesses. Patients on pegylated interferon α2a and ruxolitinib were among the most affected.

This is a side effect that rarely gets talked about, but it's real, and it matters for your quality of life.

🔬 Read the study here: https://doi.org/10.1002/jha2.15

Has this happened to you? Drop a comment below. Your experience could help other patients know they're not alone and
help us push for better conversations between patients and their care teams.

📌 Feel free to share this post so others in our community can see it.

Click on the article title to read more.

04/03/2026

Interesting new research on PV. Dr. Gerds will be on the conference call tomorrow. I'm registered, we’ll see what's up. 👊

https://finance.yahoo.com/news/an2-therapeutics-announces-plans-advance-210000259.html

02/03/2026

Tonight’s forecast. 100 percent chance of meat sweats. 🔥

Two steaks that clearly skipped leg day.

One sausage that got a little too close to the flame.

A glass of red supervising the operation. 🍷

Vegetables were invited.

They declined.

Medium rare. Slightly reckless. Fully committed.

My cardiologist just unfollowed me.😎🥩

Hope y'all had a great weekend!

20/02/2026

"Boss man" gave me permission to re-share this gem. 💎😉

Wishing everyone a safe, lovely weekend! 🌹

🩸 February is rare disease month

This cartoon shows red blood cells “gone wild,” a playful way to highlight a serious condition: Polycythemia Vera (PV).

In PV, the bone marrow produces too many red blood cells, and sometimes platelets and white blood cells. This can thicken the blood while raising the risk of clots, strokes, or other dangerous complications.

👉 Learn more and find trusted resources: https://www.pvreporter.com/

Feel free to share this post with your network.

Follow PV Reporter on Facebook for more resources and updates on MPNs.

19/02/2026

Thrombo-inflammatory endothelial signatures in JAK2-mutated myeloproliferative neoplasms (pre-print):

New research shows that in patients with Myeloproliferative Neoplasms (MPN), the lining of the blood vessels (the endothelium) is not just a passive bystander but an active driver of blood clots.

Scientists found that even though the vessels themselves do not carry the disease's primary "JAK2" mutation, they become hyper-reactive and "primed" for inflammation. This happens because the surrounding environment causes the vessel walls to release high levels of proteins that act like glue, making it much easier for life-threatening clots to form.

Essentially, the disease reprogrammed the genes of the blood vessels to be in a constant state of high alert, significantly increasing the risk of strokes and other complications.

https://www.biorxiv.org/content/10.64898/2026.02.16.706250v1

07/02/2026

Symptom-directed JAK inhibition remains standard, yet limited clonal selectivity underpins persistent progression, treatment discontinuation from intolerance, and waning spleen/symptom responses over time.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

04/02/2026

Today is World Cancer Day 2026. 👇

Since 2013, we've been dedicated to helping MPN cancer patients live better lives. PV Reporter and MPN Cancer Connection provide the tools you need to become your own advocate, connect with MPN specialists, and access educational programs on emerging treatment options.

Led by founder David Wallace and our dedicated team, we bring a unique patient perspective to the MPN community, translating complex research into actionable information you can use.

30/01/2026

Partner Corner: PV In Focus – Fort Lauderdale

Join us for a day of community and education on polycythemia vera!

📍 Fort Lauderdale, FL
📅 February 28th, 2026
🕣 8:30 AM – 2:00 PM

Topics include:

- PV overview and treatment options
- A patient's perspective
- Self-advocacy
- Mental health

Breakfast and lunch provided.

Register at PVInFocus.com

27/01/2026

Ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate response to or loss of response to existing treatments

Ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate response to or loss of response to existing treatments BURLINGTON, Mass, Jan. 27, 2026–PharmaEss...